Baseline CD317 Expression Predicting Anifrolumab Response in Lupus

31 patients with systemic lupus erythematosus were prospectively enrolled to identify biomarkers for anifrolumab response. The study, authored by Koichi Kimura, analyzed immune cell subsets and type I IFN-associated markers via flow cytometry. Baseline CD317 expression on T cells predicted 6-month clinical response with an AUC of 0.89.

Use Cases

• Analyze baseline CD317 expression on T cells to predict patient response to anifrolumab treatment.
• Compare biomarker performance between CD317 expression and the four-gene IFN gene signature (IFNGS) using DeLong's test results.
• Correlate clinical response classification (BICLA response and glucocorticoid tapering) with measured immune cell subset frequencies.
• Evaluate the discriminative power of ten significant biomarkers, including CD169 expression on monocytes and T-peripheral-helper–cell frequency.

Strengths

• Data originates from a prospective clinical study of 31 SLE patients designed to identify predictive biomarkers.
• Key findings are statistically supported, with baseline CD317 on T cells showing an AUC of 0.89 for response prediction.
• Clinical response was evaluated using two standardized criteria: BICLA response and successful glucocorticoid tapering.

Limitations

• Small sample size of 31 patients limits statistical power and generalizability of findings.
• Dataset scope is limited to the specific biomarkers and analysis presented in the accompanying research paper.
• The 10.7 KB file size indicates a summary or results table, not the underlying raw experimental data.

Provenance

Source

figshare, authored by Koichi Kimura.

Collection Method

Prospective clinical study using flow cytometry and quantitative PCR on enrolled SLE patients initiating anifrolumab.

Time Range

Clinical response was evaluated at a 6-month endpoint.

Freshness

Last updated March 2026.

Geography

null